糖尿病相关心力衰竭的发病机制、治疗及钠-葡萄糖协同转运蛋白-2抑制剂的应用  

The pathogenesis and treatment of diabetes-related heart failure and the application of sodium-glucose cotransporter-2 inhibitors

作　　者：崔洁[1] 钱菊英[1] Cui Jie;Qian Juying(Zhongshan Hospital,Fudan University,Shanghai Institute of Cardiovascular Diseases,National Clinical Research Center for Interventional Medicine)

机构地区：[1]复旦大学附属中山医院上海市心血管病研究所国家放射与治疗临床医学研究中心

出　　处：《中华心力衰竭和心肌病杂志（中英文）》2021年第2期138-144,共7页Chinese Journal of Heart Failure and Cardiomyopathy

摘　　要：糖尿病相关心力衰竭是临床常见的慢性疾病,其发病涉及多种机制。钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂在多个糖尿病相关临床试验中观察到可以改善心力衰竭患者预后,成为心力衰竭治疗领域的值得关注的药物。本文将介绍糖尿病相关心力衰竭的发病机制、SGLT-2抑制剂治疗心力衰竭的可能机制及糖尿病相关心力衰竭的临床管理,重点介绍SGLT-2抑制剂在心力衰竭中的应用。Diabetes-related heart failure is a common chronic disease in clinic,and its pathogenesis involves many mechanisms.Sodium-glucose cotransporter-2(SGLT-2)inhibitors have been observed in several diabetes-related clinical trials to improve the prognosis of patients with heart failure(HF)and have become a promising drug for the treatment of HF.This review will introduce the pathogenesis of diabetes-related heart failure,the possible mechanism of SGLT-2 inhibitors in the treatment of HF,and the clinical management of diabetes-related heart failure,with emphasis on the application of SGLT-2 inhibitors in HF.

关 键 词：糖尿病 心力衰竭 钠-葡萄糖协同转运蛋白-2抑制剂 发病机制 治疗 

分 类 号：R587.1[医药卫生—内分泌] R541.6[医药卫生—内科学]